2012
DOI: 10.1016/j.vaccine.2011.12.032
|View full text |Cite
|
Sign up to set email alerts
|

The changing and dynamic epidemiology of meningococcal disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
221
1
22

Year Published

2014
2014
2018
2018

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 263 publications
(251 citation statements)
references
References 70 publications
4
221
1
22
Order By: Relevance
“…While the incidence of invasive meningococcal disease has declined in the last decade, the United Kingdom has a higher incidence than elsewhere in Europe (17:100,000 under 5 year olds compared to 7.37:100,000 for Europe as a whole). 36,37 In keeping with changes seen following the introduction of other vaccines, the development of novel vaccines against the most common serotype B strain may dramatically change the epidemiology of meningococcal disease in the future. 38,39 Cancer statistics in children are largely classified using a system that takes into account both the site and the histology of the tumour.…”
Section: Perinatal and Congenital Causesmentioning
confidence: 99%
“…While the incidence of invasive meningococcal disease has declined in the last decade, the United Kingdom has a higher incidence than elsewhere in Europe (17:100,000 under 5 year olds compared to 7.37:100,000 for Europe as a whole). 36,37 In keeping with changes seen following the introduction of other vaccines, the development of novel vaccines against the most common serotype B strain may dramatically change the epidemiology of meningococcal disease in the future. 38,39 Cancer statistics in children are largely classified using a system that takes into account both the site and the histology of the tumour.…”
Section: Perinatal and Congenital Causesmentioning
confidence: 99%
“…They described that after testing various presentation forms of N. meningitidis PorA in mice, this protein (up to 10 mg per dose), using either AlPO 4 or QuilA as adjuvant, was unable to induce bactericidal antibodies when used for subcutaneous immunization. They additionally reported that bactericidal antibodies were produced with either the OMV of N. meningitidis B strain or PorA-ISCOM formulations.…”
Section: Discussionmentioning
confidence: 99%
“…1,3 However, the dynamics of meningococcal epidemiology is changing. 4 Several conjugated vaccines have been developed to control the severe consequences of infection. 5 The meningococcal group C conjugate (MenC) vaccine was developed by Chiron and Wyeth using N. meningitidis outer membrane vesicles and a genetically detoxified diphtheria toxoid (CMR197) as the adjuvant.…”
Section: Introductionmentioning
confidence: 99%
“…A pesar de los avances obtenidos en el manejo del paciente crítico, la EMI continua siendo un problema de salud pública, dado su amplia distribución, perfil epidémico y alta tasa de secuelas y letalidad asociada 3 . Dentro de las teorías que explican esta situación se considera la aparición y predominio del serogrupo W observada en Chile desde 2012, con una cepa del linaje hipervirulento W:P1.5,2:ST-11, la cual contiene el alelo ID 22 para el gen fHbp, que le daría la propiedad de ser hiperinvasor 4 .…”
Section: Introductionunclassified